What is the recommended starting dose and titration schedule of metoprolol tartrate for adults?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 17, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Metoprolol Tartrate Dosing for Adults

For acute coronary syndromes (STEMI/NSTEMI), start with intravenous metoprolol 5 mg every 5 minutes for up to 3 doses (15 mg total), then transition to oral metoprolol tartrate 25-50 mg every 6 hours for 48 hours, followed by maintenance dosing of 100 mg twice daily, titrating to a target of 200 mg daily as tolerated. 1, 2, 3

Acute Coronary Syndrome (STEMI/NSTEMI) Dosing

Intravenous Loading Phase

  • Initial IV dose: 5 mg administered slowly over 1-2 minutes 2, 3
  • Repeat: Every 5 minutes for up to 3 total doses (15 mg cumulative) 2, 3
  • Monitoring required: Continuous ECG, frequent blood pressure and heart rate checks, auscultation for rales and bronchospasm 2

Transition to Oral Therapy

  • Timing: 15 minutes after the last IV dose 2, 3
  • Initial oral dose: 25-50 mg every 6 hours for 48 hours 1, 2, 3
  • Maintenance dose: 100 mg twice daily thereafter 1, 2
  • Target dose: Titrate to 200 mg daily total as tolerated 1

Alternative Oral-Only Initiation

If IV administration is not indicated or safe, start with oral metoprolol tartrate at reduced doses (12.5-25 mg) within the first 24 hours 2

Heart Failure with Reduced Ejection Fraction (HFrEF)

Starting and Titration Schedule

  • Initial dose: 12.5 mg twice daily 4, 5
  • Titration interval: Increase weekly or every 1-2 weeks 6, 4
  • Target dose: 200 mg daily (100 mg twice daily) 7
  • Minimum effective dose: At least 50% of target (100 mg daily total) should be achieved if tolerated 7

Note: Metoprolol succinate (extended-release) is preferred over tartrate for heart failure, with a starting dose of 12.5-25 mg once daily, titrated to 200 mg once daily 6, 7, 4, 7. However, metoprolol tartrate has demonstrated efficacy when titrated appropriately 5, 8.

Hypertension

Standard Dosing

  • Starting dose: 100 mg once daily 9
  • Usual range: 100-200 mg daily, administered once or twice daily 10, 11
  • Maximum dose: 400 mg daily in divided doses 10
  • Titration: Increase at 2-week intervals based on blood pressure response 11

Both once-daily and twice-daily regimens are effective, with no significant difference in blood pressure control 9

Atrial Fibrillation Rate Control

Intravenous Administration

  • Dose: 2.5-5 mg IV bolus over 2 minutes 12, 13
  • Repeat: Up to 3 doses as needed 12, 13
  • Onset: 5 minutes 12, 13

Oral Maintenance

  • Dose range: 25-100 mg twice daily 12, 13
  • Typical maintenance: 50-100 mg twice daily 13

Critical Contraindications and Precautions

Absolute Contraindications to Acute Beta-Blockade

  • Signs of heart failure (rales, S3 gallop) 1, 2
  • Evidence of low output state (oliguria) 2
  • Systolic blood pressure <90 mmHg 2
  • Heart rate <50 bpm 2
  • PR interval >0.24 seconds 1
  • Second- or third-degree heart block without pacemaker 1, 2
  • Active asthma or severe reactive airways disease 1, 2

High-Risk Features for Cardiogenic Shock

Avoid IV beta-blockers if patient has: age >70 years, systolic BP <120 mmHg, sinus tachycardia >110 bpm, heart rate <60 bpm, or prolonged time since symptom onset 1

Patients with tachycardia or Killip Class II-III are at highest risk for cardiogenic shock with IV beta-blockade 2

Special Populations

Chronic Obstructive Pulmonary Disease

Use cautiously with low doses of cardioselective agent (12.5 mg metoprolol orally) rather than complete avoidance 2

Hepatic Impairment

Initiate at low doses with cautious gradual titration, as metoprolol levels increase substantially with hepatic dysfunction 3

Renal Impairment

No dose adjustment required 3

Elderly Patients (>65 years)

Use low initial starting doses given greater frequency of decreased hepatic, renal, or cardiac function 3

Target Heart Rate

The goal resting heart rate is 50-60 beats per minute unless limiting side effects occur 2

References

Research

Effects of metoprolol tartrate therapy in patients with heart failure.

Arquivos brasileiros de cardiologia, 2006

Research

Safety and efficacy of metoprolol in the treatment of hypertension in the elderly.

Journal of the American Geriatrics Society, 1992

Related Questions

Can a healthy 35-year-old adult safely use metoprolol, and what is the appropriate starting dose and dosing adjustments?
What is the maximum recommended daily dose of metoprolol (both immediate‑release tartrate and extended‑release succinate formulations)?
What is the lowest blood pressure at which metoprolol 12.5 mg can be safely initiated or continued in an adult without severe heart‑failure decompensation, bradycardia, or acute coronary ischemia?
What is the recommended dose escalation for metoprolol (Lopressor) in a patient with atrial fibrillation (AFib) with rapid ventricular response (RVR) currently taking 25mg metoprolol tartrate twice daily (BID)?
Can I increase my metoprolol succinate dose from 100 mg to 200 mg without a clinician’s supervision?
What is the recommended dosage for an isoxsuprine intravenous drip?
What are the symptoms of pancreatic cancer arising from an intraductal papillary mucinous neoplasm (IPMN)?
In patients with chronic kidney disease, is the Twynsta fixed‑dose combination (telmisartan + amlodipine) more effective than taking telmisartan and amlodipine as separate tablets?
What is the most reliable scoring tool for extubating critically ill ICU patients?
Can coronary artery disease cause syncope?
In a patient with metastatic castration‑resistant prostate cancer receiving an androgen‑receptor degrader, does a decreasing platelet count, decreasing lactate dehydrogenase, slight increase in hemoglobin, and plateauing prostate‑specific antigen indicate treatment effectiveness?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.